Dual-Source Dual-Energy CT With Additional Tin Filtration: Dose and Image Quality Evaluation in Phantoms and In Vivo
Dual-Source Dual-Energy CT With Additional Tin Filtration: Dose and Image Quality Evaluation in Phantoms and In Vivo
复制标题
DOI：
10.2214/ajr.09.3956
复制
发表时间：
2010-11-01
影响因子：
5
通讯作者：
McCollough, Cynthia H.
中科院分区：
文献类型：
--
作者：
Primak, Andrew N.;Giraldo, Juan Carlos Ramirez;McCollough, Cynthia H.
目标。该研究的目的是确定患者对碘己醇（Omnipaque）和异位钠（Gastroview）作为腹盆腔CT口服造影剂的偏好是否存在差异。第二个目的是评估两种药物在肠混浊和不良反应方面是否有显著差异。研究对象和方法。从2007年8月到2009年3月，300名患者在获得知情同意后被纳入这项前瞻性研究。符合条件的患者从门诊腹盆腔CT检查中确定。受试者被随机分配接受两种口服造影剂中的一种，采用双盲法。受试者使用5分制对味道进行评分，并收集有关人口统计、总量和不良反应的数据。然后按随机顺序对两种稀释剂各30 mL进行直接比较。由两名盲法腹部放射科医生对CT图像进行肠混浊分级。在表达偏好的287名受试者中，233名患者（81%）更倾向于稀释碘己醇，而54名患者（19%）更倾向于稀释异域酸钠（p < 0.001）。10例患者没有偏好，3例患者没有完成味觉比较研究。两种口服造影剂在肠混浊方面无显著差异（p = 0.27），不良反应方面也无显著差异（p = 0.352）。在腹部-骨盆CT的口服造影剂中，专利更倾向于稀碘己醇而不是稀散钠。两组在肠混浊或不良反应方面无显著差异。
OBJECTIVE. The purpose of the study was to determine whether a difference in patient preference exists between iohexol (Omnipaque) and diatrizoate sodium (Gastroview) as oral contrast medium for abdominal-pelvic CT. A secondary objective was to evaluate whether there are significant differences in bowel opacification and adverse effect profile for the two agents.SUBJECTS AND METHODS. From August 2007 through March 2009, 300 patients were enrolled in this prospective study after informed consent was obtained. Eligible patients were identified from those scheduled for outpatient abdominal-pelvic CT. Subjects were randomly assigned to receive one of two oral contrast agents in a double-blinded fashion. Subjects graded the taste using a 5-point scale, and data regarding demographics, total volume, and adverse effects were collected. A direct comparison of 30 mL of each of the two diluted agents in randomized order was then performed. CT images were graded for bowel opacification by two blinded abdominal radiologists.RESULTS. Of 287 subjects who expressed a preference, 233 patients (81%) preferred dilute iohexol compared with 54 patients (19%) who preferred dilute diatrizoate sodium (p < 0.001). Ten patients had no preference, and three patients did not complete the taste comparison study. No difference in bowel opacification was identified between the oral contrast agents (p = 0.27), nor was there a significant difference in adverse effects (p = 0.352).CONCLUSION. Patents preferred dilute iohexol over dilute diatrizoate sodium for oral contrast for abdominal-pelvic CT. There was no significant difference in bowel opacification or adverse effect profile.